Related Experiment Video
Updated: Apr 19, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient
Stephanie Lu1, Michele C Azada2, Sai-Hong Ignatius Ou3
1Gavin Herbert Eye Institute, Department of Ophthalmology, University of California Irvine School of Medicine, Orange, CA 92868, United States.
Objectives:
Choroidal metastases are uncommon metastasis from non-small cell lung cancer (NSCLC). With improved survival from the use of targeted therapy against actionable driver mutation driven NSCLC, the incidence of choroidal metastases seems to be increasing. Recently, there are several case reports of choroidal metastases in patients with anaplastic lymphoma kinase (ALK)-driven NSCLC one of which the patient's choroidal metastases had responded to crizotinib, multi-targeted tyrosine kinase inhibitor against ALK/ROS1/MET. Similarly ROS1-rearranged NSCLC has very similar clinicopathologic characteristics as ALK-rearranged NSCLC and crizotinib has demonstrated significant clinical activity against ROS1-rearranged NSCLC.
Materials And Methods:
Here in this report we presented a patient with ROS1-rearranged NSCLC that presented with choroidal metastases that did not respond to initial chemotherapy but had a rapid and complete response to crizotinib.
Conclusions:
Although likely to be exceeding rare, choroidal metastases from ROS1-rearranged NSCLC can be successfully treated with crizotinib similar to choroidal metastases from ALK-rearranged NSCLC can be successfully treated from another case report.
Insights
Choroidal metastases from ROS1-rearranged non-small cell lung cancer (NSCLC) are rare but treatable. Crizotinib, a targeted therapy, showed rapid and complete response in a patient unresponsive to chemotherapy.
Area of Science:
- Oncology
- Ophthalmology
- Genetics
Background:
- Choroidal metastases are uncommon in non-small cell lung cancer (NSCLC).
- Improved survival in NSCLC due to targeted therapies may increase the incidence of choroidal metastases.
- Anaplastic lymphoma kinase (ALK)-driven NSCLC with choroidal metastases has shown response to crizotinib.
Observation:
- This report details a patient with ROS1-rearranged NSCLC presenting with choroidal metastases.
- The patient's metastases did not respond to initial chemotherapy.
- A rapid and complete response to crizotinib was observed.
Findings:
- ROS1-rearranged NSCLC shares clinicopathologic similarities with ALK-rearranged NSCLC.
- Crizotinib, a multi-targeted tyrosine kinase inhibitor, is effective against ROS1-rearranged NSCLC.
- Choroidal metastases in ROS1-rearranged NSCLC can be successfully treated with crizotinib.
Implications:
- Crizotinib represents a potential treatment for rare cases of choroidal metastases in ROS1-rearranged NSCLC.
- This finding aligns with successful crizotinib treatment for choroidal metastases in ALK-rearranged NSCLC.
- Further investigation into targeted therapies for rare NSCLC metastases is warranted.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Related Concept Videos
02:56Treatment Resistent Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...